Search results
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
InvestorPlace via Yahoo Finance· 7 months agoAutologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new...
Gilead expands Arcellx cancer cell therapy deal
BioPharma Dive via Yahoo Finance· 6 months agoDive Brief: Gilead is expanding its collaboration with cancer cell therapy developer Arcellx, announcing Wednesday that subsidiary Kite Pharma has used...
Designer immune-cell therapy could shrink deadly brain tumors, early trials show
Live Science via Yahoo News· 2 months agoTwo early clinical trials that together included nine patients suggest that a treatment called CAR-T...
Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology
Zacks via Yahoo Finance· 1 year agoGilead’s GILD wholly owned subsidiary Kite announced a global strategic collaboration with a...
Could CRISPR cure HIV someday?
Live Science via Yahoo News· 5 months agoClose-up of a gloved hand using tweezers to pull genetic material from a suspended DNA molecule. In an ongoing clinical trial, researchers are testing...
Arcellx (ACLX) Up 5% on Partnership Expansion With Gilead
Zacks via Yahoo Finance· 6 months agoShares of Arcellx ACLX moved up 5.3% on Wednesday after the company announced that it is expanding...
Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?
Zacks via Yahoo Finance· 5 months agoGilead Sciences, Inc.’s GILD shares have gained 3.7% in the past six months against the industry’s...
FDA approves CAR-T therapies from J&J, Bristol Myers for earlier myeloma use
BioPharma Dive via Yahoo Finance· 1 month agoThe FDA quickly followed last week’s clearance of Bristol Myers’ Abecma with an OK for J&J’s...
Arcellx (RCLX) Down on Hold for Lead Program CART-ddBCMA
Zacks via Yahoo Finance· 11 months agoArcellx's (ACLX) study on lead program CART-ddBCMA for treating adult patients with relapsed or...
Poseida Therapeutics Ushers New Era For Gene Therapies, Analyst Initiating Coverage Says
Benzinga via Yahoo Finance· 1 year agoHC Wainwright has initiated coverage on Poseida Therapeutics Inc (NASDAQ: PSTX) with a Buy rating...
